GSK's Depemokimab Shows 54% Asthma Exacerbation Reduction
Ticker: GLAXF · Form: 6-K · Filed: Sep 9, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Sep 9, 2024 |
| Risk Level | low |
| Pages | 8 |
| Reading Time | 9 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial-data, pharmaceuticals, respiratory-disease
TL;DR
GSK's depemokimab crushed severe asthma exacerbations by 54% in Phase III trials.
AI Summary
GSK plc announced on September 9, 2024, that late-breaking data from its SWIFT-1 and SWIFT-2 Phase III trials for depemokimab were presented at ERS. The data demonstrated a 54% reduction in severe asthma exacerbations in patients treated with depemokimab.
Why It Matters
This positive data could lead to a new treatment option for severe asthma, potentially improving patient outcomes and GSK's respiratory franchise.
Risk Assessment
Risk Level: low — This is a routine 6-K filing reporting positive clinical trial data, which is standard for pharmaceutical companies.
Key Numbers
- 54% — Reduction in severe asthma exacerbations (Demonstrated by depemokimab in SWIFT-1 and SWIFT-2 trials.)
Key Players & Entities
- GSK plc (company) — Registrant
- depemokimab (drug) — Investigational treatment
- SWIFT-1 (clinical_trial) — Phase III trial for depemokimab
- SWIFT-2 (clinical_trial) — Phase III trial for depemokimab
- ERS (conference) — European Respiratory Society congress
- 54% (percentage) — Reduction in severe asthma exacerbations
- September 9, 2024 (date) — Date of issuance
FAQ
What specific patient population was studied in the SWIFT-1 and SWIFT-2 trials?
The filing states that depemokimab showed a 54% reduction in severe asthma exacerbations, implying the study focused on patients with severe asthma.
When were the SWIFT-1 and SWIFT-2 trials conducted?
The filing does not specify the exact dates of the SWIFT-1 and SWIFT-2 trials, only that late-breaking data was presented at ERS on September 9, 2024.
What is the mechanism of action for depemokimab?
The filing does not detail the mechanism of action for depemokimab.
Has GSK plc filed for regulatory approval of depemokimab based on this data?
The filing does not mention any regulatory filings for depemokimab.
What is the significance of presenting data at ERS?
ERS (European Respiratory Society) is a major congress for respiratory medicine, indicating the data is considered significant within the field.
Filing Stats: 2,344 words · 9 min read · ~8 pages · Grade level 11.5 · Accepted 2024-09-09 09:58:15
Filing Documents
- a4305d.htm (6-K) — 66KB
- 0001654954-24-011612.txt ( ) — 67KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: September 09, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc